BIAFFIN GmbH & Co. KG   Report issue

For profit Phase 2
Founded: Kassel Germany (2000)
Status: No NME R&D (2000)

Organization Overview

First Clinical Trial
2009
NCT00918281
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Alternative names

BIAFFIN GmbH & Co. KG (Biomolecular Interaction Analyses)

Active Ingredients

Drugs in Phase 2 Trials (1)

18f-fluciclatide (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Renal Cell (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1